Search Results - Demuth, Dirk

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study

    Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study by Carroll, Stuart, Gater, Adam, Abetz-Webb, Linda, Smith, Fiona, Demuth, Dirk, Mannan, Azharul

    Published 2013
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Pulmonary function testing in the Emergency Department and medications prescribed at discharge: results of the Multinational Acute asthma Management, Burden, and Outcomes (MAMBO) study

    Pulmonary function testing in the Emergency Department and medications prescribed at discharge: results of the Multinational Acute asthma Management, Burden, and Outcomes (MAMBO) s... by Fitzgerald, J Mark, O'Byrne, Paul M, McFetridge, Jeffrey T, Demuth, Dirk, Allen-Ramey, Felicia C

    Published 2010
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    Allergy immunotherapy prescribing trends for grass pollen-induced allergic rhinitis in Germany: a retrospective cohort analysis

    Allergy immunotherapy prescribing trends for grass pollen-induced allergic rhinitis in Germany: a retrospective cohort analysis by McDonell, Amanda L., Wahn, Ulrich, Demuth, Dirk, Richards, Catrina, Hawes, Charlie, Andreasen, Jakob Nørgaard, Allen-Ramey, Felicia

    Published 2015
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    Early Intervention With Vedolizumab and Longer-term Surgery Rates in Crohn’s Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programmes

    Early Intervention With Vedolizumab and Longer-term Surgery Rates in Crohn’s Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programmes by Dulai, Parambir S, Peyrin-Biroulet, Laurent, Demuth, Dirk, Lasch, Karen, Hahn, Kristen A, Lindner, Dirk, Patel, Haridarshan, Jairath, Vipul

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study

    Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study by Ooi, Choon Jin, Hilmi, Ida Normiha, Kim, Hyo-Jong, Jalihal, Umesh, Wu, Deng-Chyang, Demuth, Dirk, Lindner, Dirk, Adsul, Shashi

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study

    Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study by Banerjee, Rupa, Chuah, Sai Wei, Hilmi, Ida Normiha, Wu, Deng-Chyang, Yang, Suk-Kyun, Demuth, Dirk, Lindner, Dirk, Adsul, Shashi

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease

    Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease by Schreiber, Stefan, Dignass, Axel, Peyrin-Biroulet, Laurent, Hather, Greg, Demuth, Dirk, Mosli, Mahmoud, Curtis, Rebecca, Khalid, Javaria Mona, Loftus, Edward Vincent

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE study

    A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE study by Cummings, Fraser, Gaya, Daniel R., Levison, Scott, Subramanian, Sreedhar, Owen, Glynn, Rathmell, Anna, Glen, Fiona, Demuth, Dirk, Meadowcroft, Simon, Irving, Peter M.

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  9. 9
    Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study

    Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study by Li, Ji, Liu, Zhanju, Hu, Pinjin, Wen, Zhonghui, Cao, Qian, Zou, Xiaoping, Chen, Yan, Wang, Yingde, Zhong, Jie, Shen, Xizhong, Demuth, Dirk, Fadeeva, Olga, Xie, Li, Chen, Jun, Qian, Jiaming

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  10. 10
    Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study

    Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study by Bressler, Brian, Yarur, Andres, Silverberg, Mark S, Bassel, Marielle, Bellaguarda, Emanuelle, Fourment, Chris, Gatopoulou, Anthie, Karatzas, Pantelis, Kopylov, Uri, Michalopoulos, George, Michopoulos, Spyridon, Navaneethan, Udayakumar, Rubin, David T, Siffledeen, Jesse, Singh, Andrew, Soufleris, Konstantinos, Stein, Dara, Demuth, Dirk, Mantzaris, Gerassimos J

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: